{"id":"https://openalex.org/W4220859629","doi":"https://doi.org/10.1111/bcp.15305","title":"A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK\u2010041 in healthy participants and patients with stable schizophrenia","display_name":"A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK\u2010041 in healthy participants and patients with stable schizophrenia","publication_year":2022,"publication_date":"2022-03-12","ids":{"openalex":"https://openalex.org/W4220859629","doi":"https://doi.org/10.1111/bcp.15305","pmid":"https://pubmed.ncbi.nlm.nih.gov/35277995","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9544063"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.15305","doi":"https://doi.org/10.1111/bcp.15305","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15305","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15305","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15305","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039368137","display_name":"Wei Yin","orcid":"https://orcid.org/0000-0002-4834-5783","observed_orcids":["https://orcid.org/0000-0002-4834-5783"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Wei Yin","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-4834-5783","affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114155555","display_name":"David Han","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Han","raw_affiliation_strings":["Parexel, Glendale, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel, Glendale, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030949544","display_name":"Polyna Khudyakov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Polyna Khudyakov","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044935130","display_name":"Rhett Behrje","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rhett Behrje","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070558567","display_name":"Joel A. Posener","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joel Posener","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045681106","display_name":"Antonio Laurenza","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antonio Laurenza","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079209617","display_name":"Dimitrios Arkilo","orcid":"https://orcid.org/0000-0002-7487-2747","observed_orcids":["https://orcid.org/0000-0002-7487-2747"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dimitrios Arkilo","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5039368137"],"corresponding_institution_ids":[],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":{"value":4200,"currency":"USD","value_usd":4200},"fwci":1.7819,"has_fulltext":true,"cited_by_count":15,"citation_normalized_percentile":{"value":0.84364912,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"88","issue":"8","first_page":"3872","last_page":"3882"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gpr139","display_name":"GPR139","score":0.8880000114440918},{"id":"https://openalex.org/keywords/orphan-gpcrs","display_name":"orphan G protein-coupled receptor","score":0.871999979019165},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9039999842643738},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9089999794960022},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.9229999780654907},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.8820000290870667},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.5979999899864197},{"id":"https://openalex.org/keywords/anxiety-and-depression","display_name":"anxiety and depression","score":0.5130000114440918},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5270000100135803}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8594680428504944},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.69190514087677},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6286937594413757},{"id":"https://openalex.org/C2780135775","wikidata":"https://www.wikidata.org/wiki/Q7233251","display_name":"Positive and Negative Syndrome Scale","level":3,"score":0.6134945750236511},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.60272216796875},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6007305979728699},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4857218861579895},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.4520173668861389},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.4256579279899597},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3676171898841858},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.3400287628173828},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.28011900186538696}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/bcp.15305","doi":"https://doi.org/10.1111/bcp.15305","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15305","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15305","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9544063","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9544063","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:35277995","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35277995","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/bcp.15305","doi":"https://doi.org/10.1111/bcp.15305","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15305","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15305","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310465","display_name":"Takeda Pharmaceutical Company","ror":"https://ror.org/04hjbmv12"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4220859629.pdf","grobid_xml":"https://content.openalex.org/works/W4220859629.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1151536748","https://openalex.org/W2069025205","https://openalex.org/W2087633698","https://openalex.org/W2104255009","https://openalex.org/W2105527159","https://openalex.org/W2130145042","https://openalex.org/W2167179481","https://openalex.org/W2218409913","https://openalex.org/W2232576328","https://openalex.org/W2413671571","https://openalex.org/W2562216088","https://openalex.org/W2733289983","https://openalex.org/W2866827471","https://openalex.org/W2918655864","https://openalex.org/W3027068636","https://openalex.org/W3199710005","https://openalex.org/W3201244536","https://openalex.org/W3206698686","https://openalex.org/W4211145950"],"related_works":["https://openalex.org/W3180508219","https://openalex.org/W4413257608","https://openalex.org/W2509237794","https://openalex.org/W2769201758","https://openalex.org/W2601155082","https://openalex.org/W4390223671","https://openalex.org/W2889703975","https://openalex.org/W308233349","https://openalex.org/W2796616676","https://openalex.org/W2195641759"],"abstract_inverted_index":{"AIMS:":[0],"TAK-041":[1,48,57,140,227,242],"(NBI-1065846),":[2],"an":[3,12],"orally":[4],"available,":[5],"investigational,":[6],"small":[7],"molecule":[8],"agonist":[9],"of":[10,25,47,56,114,153,193,201,219,241],"GPR139,":[11],"orphan":[13],"G-protein-coupled":[14],"receptor,":[15],"has":[16],"shown":[17],"promise":[18],"in":[19,49,63,80,86,128,197,222,232,243],"preclinical":[20],"studies":[21],"for":[22,182,187,213],"the":[23,33,42,112,164,198,202,216],"treatment":[24],"symptoms":[26],"associated":[27],"with":[28,65,88,130,147,184,224,237,245],"schizophrenia.":[29,90,132,225,238],"Here,":[30],"we":[31],"report":[32],"results":[34],"from":[35],"a":[36,94,100,124,142],"phase":[37],"1":[38,92],"study":[39,72,102,127],"to":[40,61],"evaluate":[41],"safety,":[43],"tolerability":[44],"and":[45,52,83,107,120,150,167,170,204,215,235],"pharmacokinetics":[46,145],"healthy":[50,81,188,233],"adults":[51,64,82,236],"exploratory":[53],"efficacy":[54],"assessment":[55],"as":[58],"adjunctive":[59],"therapy":[60],"antipsychotics":[62],"stable":[66,89,131],"schizophrenia":[67,185,246],"(ClinicalTrials.gov:":[68],"NCT02748694).":[69],"METHODS:":[70],"The":[71],"comprised":[73],"4":[74,85,122],"parts:":[75],"parts":[76],"1-3":[77],"were":[78,138],"undertaken":[79],"part":[84,97,109,121],"patients":[87,129,183,223],"Part":[91],"was":[93,99,123,161,175,179,195,228],"single-rising-dose":[95],"study,":[96],"2":[98],"multiple-rising-dose":[101],"that":[103],"assessed":[104],"plasma":[105],"exposure":[106,178],"accumulation,":[108],"3":[110],"evaluated":[111],"bioavailability":[113],"tablet":[115,165],"formulation":[116,166],"versus":[117],"oral":[118,168],"suspension,":[119,169],"repeat":[125],"multiple-dose":[126],"RESULTS:":[133],"No":[134],"serious":[135],"adverse":[136],"events":[137],"reported.":[139],"had":[141],"nearly":[143],"linear":[144],"profile,":[146],"rapid":[148],"absorption":[149],"long":[151],"half-life":[152],"170-302":[154],"hours":[155],"across":[156],"all":[157],"doses":[158],"tested.":[159],"Bioavailability":[160],"similar":[162],"between":[163],"no":[171],"meaningful":[172],"food":[173],"effect":[174],"detected.":[176],"Systemic":[177],"22-30%":[180],"lower":[181],"than":[186],"volunteers.":[189],"A":[190],"potential":[191],"signal":[192],"improvement":[194],"detected":[196],"anxiety-depression":[199],"scale":[200],"Positive":[203],"Negative":[205],"Syndrome":[206],"Scale":[207,221],"(P":[208],"=":[209],".0002,":[210],"not":[211],"corrected":[212],"multiplicity)":[214],"Temporal":[217],"Experience":[218],"Pleasure":[220],"CONCLUSION:":[226],"generally":[229],"well":[230],"tolerated":[231],"volunteers":[234],"Further":[239],"investigation":[240],"individuals":[244],"is":[247],"supported.":[248]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2022-04-03T00:00:00"}